Serum-soluble E-cadherin fragments in lung cancer

Michele Cioffi, Patrizia Gazzerro, Bruno Di Finizio, Maria Teresa Vietri, Catia Di Macchia, Giovanni Alfredo Puca, Anna Maria Molinari

Research output: Contribution to journalArticle

Abstract

Aims and background: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA 2+-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. Methods and study design: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. Results: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. Conclusions: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.

Original languageEnglish
Pages (from-to)32-34
Number of pages3
JournalTumori
Volume85
Issue number1
Publication statusPublished - Jan 1999

Fingerprint

Cadherins
Lung Neoplasms
Serum
Breast Neoplasms
Small Cell Carcinoma
Cell Adhesion Molecules
Tumor Biomarkers
Immunoenzyme Techniques
Squamous Cell Carcinoma
Stomach
Adenocarcinoma
Lung

Keywords

  • E-cadherin
  • IEMA method
  • Lung cancer
  • Tumor marker

ASJC Scopus subject areas

  • Cancer Research

Cite this

Cioffi, M., Gazzerro, P., Di Finizio, B., Vietri, M. T., Di Macchia, C., Puca, G. A., & Molinari, A. M. (1999). Serum-soluble E-cadherin fragments in lung cancer. Tumori, 85(1), 32-34.

Serum-soluble E-cadherin fragments in lung cancer. / Cioffi, Michele; Gazzerro, Patrizia; Di Finizio, Bruno; Vietri, Maria Teresa; Di Macchia, Catia; Puca, Giovanni Alfredo; Molinari, Anna Maria.

In: Tumori, Vol. 85, No. 1, 01.1999, p. 32-34.

Research output: Contribution to journalArticle

Cioffi, M, Gazzerro, P, Di Finizio, B, Vietri, MT, Di Macchia, C, Puca, GA & Molinari, AM 1999, 'Serum-soluble E-cadherin fragments in lung cancer', Tumori, vol. 85, no. 1, pp. 32-34.
Cioffi M, Gazzerro P, Di Finizio B, Vietri MT, Di Macchia C, Puca GA et al. Serum-soluble E-cadherin fragments in lung cancer. Tumori. 1999 Jan;85(1):32-34.
Cioffi, Michele ; Gazzerro, Patrizia ; Di Finizio, Bruno ; Vietri, Maria Teresa ; Di Macchia, Catia ; Puca, Giovanni Alfredo ; Molinari, Anna Maria. / Serum-soluble E-cadherin fragments in lung cancer. In: Tumori. 1999 ; Vol. 85, No. 1. pp. 32-34.
@article{b2861caac30741608ce0bc18fe47c061,
title = "Serum-soluble E-cadherin fragments in lung cancer",
abstract = "Aims and background: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA 2+-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. Methods and study design: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. Results: At a specificity level of 90{\%}, E-cadherin diagnostic sensitivity was 66.6{\%}, 47.6{\%} and 43.7{\%} in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. Conclusions: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.",
keywords = "E-cadherin, IEMA method, Lung cancer, Tumor marker",
author = "Michele Cioffi and Patrizia Gazzerro and {Di Finizio}, Bruno and Vietri, {Maria Teresa} and {Di Macchia}, Catia and Puca, {Giovanni Alfredo} and Molinari, {Anna Maria}",
year = "1999",
month = "1",
language = "English",
volume = "85",
pages = "32--34",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Serum-soluble E-cadherin fragments in lung cancer

AU - Cioffi, Michele

AU - Gazzerro, Patrizia

AU - Di Finizio, Bruno

AU - Vietri, Maria Teresa

AU - Di Macchia, Catia

AU - Puca, Giovanni Alfredo

AU - Molinari, Anna Maria

PY - 1999/1

Y1 - 1999/1

N2 - Aims and background: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA 2+-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. Methods and study design: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. Results: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. Conclusions: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.

AB - Aims and background: E-cadherin, also known as uvomorulin or cell-CAM 120/80, is one of the subclasses of cadherins, CA 2+-dependent cell adhesion molecules. Several recent studies have suggested that loss of E-cadherin may be associated with tumor progression, such as in lung, gastric, hepatocellular, breast and prostatic carcinoma. Assessment of E-cadherin serum levels in lung cancer showed a relation to histologic type. Methods and study design: Using an enzyme immunoassay, we determined E-cadherin serum levels in 79 patients affected with lung cancer (stage I-IV), 9 patients with breast cancer, 23 patients with different benign diseases, and 20 healthy patients. Results: At a specificity level of 90%, E-cadherin diagnostic sensitivity was 66.6%, 47.6% and 43.7% in patients affected with squamous cell carcinoma, small cell carcinoma and adenocarcinoma, respectively. Conclusions: Preliminary results suggest the use of serum E-cadherin as a prospective tumor marker.

KW - E-cadherin

KW - IEMA method

KW - Lung cancer

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=0033045449&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033045449&partnerID=8YFLogxK

M3 - Article

C2 - 10228494

AN - SCOPUS:0033045449

VL - 85

SP - 32

EP - 34

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -